Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Predicting microvascular invasion in hepatocellular carcinoma using contrast-enhanced CT-based deep learning models: a comparative study of transformer, CNN, and MIL.

Created on 17 Nov 2026

Authors

Mianlei Lin, Xiaojun Zheng, Caitao Zhao, Tao Lin, Qishu Zhao

Published in

Frontiers in oncology. Volume 16. Pages 1988882. Epub Nov 02, 2026.

Abstract

Microvascular invasion (MVI) predicts postoperative recurrence in hepatocellular carcinoma (HCC), yet preoperative prediction remains challenging. This study compared a Transformer, a convolutional neural network (CNN), and a multiple instance learning (MIL) framework for predicting MVI from contrast-enhanced CT.
We retrospectively enrolled 236 patients with pathologically confirmed HCC. Tumor regions of interest were semi-automatically delineated on arterial-phase CT images, and slices centered on the largest tumor cross-section were sampled to build a 2.5D dataset. Four models-Transformer, MIL, CNN, and a clinical baseline-were trained. Models were compared using the area under the receiver operating characteristic curve (AUC) with the DeLong test; bootstrap resampling assessed the stability of AUC estimates.
The Transformer achieved the highest AUC of 0.827 (95% CI 0.7585-0.8962), with an accuracy of 0.775, sensitivity of 0.577, and specificity of 0.889, followed by MIL (0.766; 95% CI 0.6875-0.8441), CNN (0.723), and the clinical model (0.715). Bootstrap validation confirmed stable AUC estimates for all models, with the Transformer ranking first (mean 0.827; SD 0.034). The Transformer significantly outperformed the CNN (adjusted P = 0.001) and the clinical model (adjusted P = 0.039); after correction for multiple comparisons, its difference from MIL was of borderline significance (adjusted P = 0.097). No significant differences were observed among the CNN, MIL, and clinical models.
Among the four models evaluated, the contrast-enhanced CT-based Transformer predicted MVI most accurately, and its advantage persisted after bootstrap internal validation. These findings concern the ranking of discriminative performance only; the clinical utility of the model is not established, and prospective validation in larger cohorts is required before any clinical application.

PMID:
43041403
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement